Fresenius Kabi’s large-scale sterile injectables plant in Melrose Park near Chicago, which was in 2020 the recipient of multiple Form 483 deficiencies, has received its long-awaited US Food and Drug Administration inspection, the German firm has confirmed.
“We expect feedback over the course of the third quarter,” the Fresenius group CEO Stephan Sturm told investors during the